Welcome to our dedicated page for Immunitybio news (Ticker: IBRX), a resource for investors and traders seeking the latest updates and insights on Immunitybio stock.
ImmunityBio, Inc. (NASDAQ: IBRX) generates frequent news as a commercial-stage biotechnology company centered on IL‑15–based immunotherapies and cell therapies. Its updates often highlight clinical data, regulatory milestones, and commercial performance for ANKTIVA, an IL‑15 receptor agonist fusion complex that the company describes as a key component of its BioShield platform.
News coverage commonly focuses on bladder cancer and non‑small cell lung cancer (NSCLC). For non‑muscle invasive bladder cancer, ImmunityBio reports results from the QUILT‑3.032 trial of ANKTIVA plus BCG in BCG‑unresponsive disease, including data on disease‑specific survival, progression‑free survival, and cystectomy avoidance. For NSCLC, press releases describe findings from QUILT‑2.023 and QUILT‑3.055, where ANKTIVA combined with checkpoint inhibitors has been associated with immune restoration, measured by absolute lymphocyte count, and linked to survival outcomes in checkpoint‑experienced patients.
Regulatory developments are another major news theme. Recent announcements include a conditional marketing authorization recommendation from the European Medicines Agency for ANKTIVA plus BCG in BCG‑unresponsive NMIBC CIS, as well as Saudi Food and Drug Authority approvals for ANKTIVA plus BCG in NMIBC CIS and for ANKTIVA in combination with checkpoint inhibitors in metastatic NSCLC, including the first approval for subcutaneous administration. These items illustrate how ImmunityBio’s news flow tracks the global expansion of ANKTIVA‑based regimens.
Investors and observers can also expect news on financial results and product revenue, particularly net product revenue and unit growth for ANKTIVA, along with cash position and capital‑raising activities disclosed in earnings releases and related Form 8‑K filings. Additional stories cover early data in glioblastoma using ANKTIVA plus NK cell therapy and the Optune Gio device, initiatives in non‑Hodgkin lymphoma and other cancers, and participation in forums such as the U.S.–Saudi Biotech Alliance Summit.
By following ImmunityBio’s news page, readers can track clinical trial progress, new approvals, and commercial trends that shape the outlook for IBRX and its IL‑15–based immunotherapy programs.
ImmunityBio, Inc. (NASDAQ: IBRX) announces that Executive Chairman Patrick Soon-Shiong, M.D., will deliver the 2023 David Packard Award Lecture at the Uniformed Services University in Bethesda, MD, on April 25. This lecture recognizes his pioneering contributions to cancer therapies and immunotherapy, specifically discussing the activation of natural killer and T cells for cancer treatment. Dr. Soon-Shiong's illustrious career includes significant achievements in immunology and over 500 patents. He founded American Pharmaceutical Partners and developed Abraxane, a groundbreaking chemotherapy drug. The lecture is part of an annual event honoring David Packard, a key figure in U.S. defense and education. ImmunityBio focuses on developing advanced immunotherapies for cancer and infectious diseases.
ImmunityBio, Inc. (NASDAQ: IBRX) announced that Dr. Karim Chamie from UCLA will present findings from the QUILT 3.032 study at the ASCO GU conference in San Francisco from February 16-18. This study assesses the quality of life for patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) receiving N-803 combined with BCG. Results showed improved physical function among responders and highlighted a favorable risk/benefit ratio. The FDA is reviewing the Biologics License Application for N-803, with a PDUFA date set for May 23, 2023.
ImmunityBio, Inc. (NASDAQ: IBRX) has announced a registered direct offering to institutional investors, aiming to raise approximately $50 million in gross proceeds. The financing involves the issuance of common stock and warrants for additional shares, potentially generating up to $60 million if the warrants are fully exercised. This funding is intended to bolster working capital and support ongoing operations. Jefferies LLC acts as the exclusive placement agent for the offering. ImmunityBio is focused on developing innovative immunotherapies targeting cancers and infectious diseases, with its lead candidate N-803 currently under FDA review for bladder cancer.
ImmunityBio, identified by NASDAQ: IBRX, announced positive outcomes from its Phase 2 study on metastatic pancreatic cancer, QUILT 88. The study involved 83 patients and showed a median overall survival (OS) of 5.8 months, significantly higher than historical rates of 2-3 months. In the third-line cohort, the median OS reached 6.3 months. Notably, 61% of patients demonstrated disease control. The company held discussions with the FDA regarding registration pathways for pancreatic cancer and NMIBC. A randomized trial is in place for second-line patients, with 25 enrolled to date.
ImmunityBio has secured approximately $50 million in equity financing and $50 million in debt financing from Nant Capital, LLC. The financing also includes a conversion of $56.6 million in debt from NantWorks LLC into equity at a price of $5.67 per share. Furthermore, up to $60 million may be raised through warrants over two years. The funds will be utilized for pre-commercialization, clinical development, and general corporate purposes.
LadRx Corporation (OTCQB: LADX) provides a quarterly update for Q3 2022, highlighting its biopharmaceutical advancements, particularly in cancer therapeutics. The company focuses on its LADR technology, enabling targeted chemotherapeutic delivery. Key developments include the next-gen LADR drug candidates LADR7-10 and the progress of Aldoxorubicin, now in clinical trials under Immunity Bio (NASDAQ: IBRX). Financially, LadRx aims to extend its cash runway into mid-2023 while seeking additional funding amidst challenging market conditions.
ImmunityBio, Inc. (NASDAQ: IBRX) announced its participation in the 34th Annual Piper Sandler Healthcare Conference in location value="LU/us.ny.nyc"New York City from November 29 - December 1, 2022. The presentation is scheduled for November 29 at 2:30 - 2:55 pm EST, featuring a fireside chat with Director and Senior Research Analyst, Joseph Catanzaro, Ph.D. A webcast will be available for those interested. ImmunityBio focuses on developing next-generation immunotherapies and vaccines, currently conducting 27 clinical trials across various cancer and infectious disease indications.
ImmunityBio's QUILT 3.032 trial results for N-803 plus BCG show promising efficacy for bladder cancer patients. In the carcinoma in situ cohort, 71% achieved complete response (CR) with a median duration of 26.6 months. The treatment demonstrated a 90% probability of avoiding cystectomy in responders. In the NMIBC cohort, 55% remained disease-free at 12 months. The FDA is reviewing the Biologics License Application for this combination therapy, with a decision expected by May 23, 2023. N-803's safety profile was comparable to BCG alone, indicating its potential role in treating BCG-unresponsive bladder cancer.
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, will present at the Jefferies London Healthcare Conference in London from November 15-17, 2022. The presentation is scheduled for November 15 from 4:25–4:55 PM BST and will include a corporate presentation followed by a Q&A session. A webcast link for the presentation is available online, and a replay will be archived for 90 days. ImmunityBio is focused on developing therapies and vaccines to enhance the immune system against cancers and infectious diseases, with a clinical pipeline of 27 trials.
Faraday Future has appointed Yun Han as Chief Accounting Officer and Interim Chief Financial Officer, effective October 25, 2022. Han replaces Becky Roof, who served in the interim role until October 12, 2022. The company expects to receive $10 million this week as part of a $60 million financing agreement, following the successful acquisition of $55 million in financing. The funds will support Faraday Future’s operations and its efforts to bring the FF 91 to market. CEO Dr. Carsten Breitfeld expressed confidence in Han’s experience and the company’s growth potential.